Psoriatic arthritis (PsA) is a chronic joint disease found on patients with psoriasis. It is one of the diseases in the spondyloarthritis (SpA) spectrum. Unlike rheumatoid arthritis, PsA doesnt have a specific biomarker to aid in its diagnosis. While its mortality is still debatable, its morbidity is not. PsA pathophysiology is nowadays more understood, but its precise mechanism is still unclear. One of the contributors is dysbiosis, which in turn lead to an increase in T helper 17 (Th17) cells that promote autoimmunity. There can be articular/periarticular and extraarticular manifestations in PsA. Currently, the best method to diagnose PsA is by using the CASPAR (Classification criteria for Psoriatic Arthritis) criteria, which has good specificity and sensitivity. To monitor disease activity, the Indonesian Rheumatology Association (IRA) recommends the use of DAPSA (Disease Activity in Psoriatic Arthritis) score. Treatment for PsA can be pharmacological and nonpharmacological. Its treatment goal is remission or low disease activity.